Find Rufinamide manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

KDMF

KDMF

0

VMF

NDC API

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF DossiersDRUG PRODUCT COMPOSITIONS

197RELATED EXCIPIENT COMPANIES

324EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

API REF. PRICE (USD/KG)

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 106308-44-5, Banzel, Inovelon, 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide, Cgp 33101, Cgp-33101
Molecular Formula
C10H8F2N4O
Molecular Weight
238.19  g/mol
InChI Key
POGQSBRIGCQNEG-UHFFFAOYSA-N
FDA UNII
WFW942PR79

Rufinamide
Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures.
1 2D Structure

Rufinamide

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
1-[(2,6-difluorophenyl)methyl]triazole-4-carboxamide
2.1.2 InChI
InChI=1S/C10H8F2N4O/c11-7-2-1-3-8(12)6(7)4-16-5-9(10(13)17)14-15-16/h1-3,5H,4H2,(H2,13,17)
2.1.3 InChI Key
POGQSBRIGCQNEG-UHFFFAOYSA-N
2.1.4 Canonical SMILES
C1=CC(=C(C(=C1)F)CN2C=C(N=N2)C(=O)N)F
2.2 Other Identifiers
2.2.1 UNII
WFW942PR79
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide

2. Cgp 33101

3. Cgp-33101

4. Inovelon

2.3.2 Depositor-Supplied Synonyms

1. 106308-44-5

2. Banzel

3. Inovelon

4. 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide

5. Cgp 33101

6. Cgp-33101

7. 1-[(2,6-difluorophenyl)methyl]-1h-1,2,3-triazole-4-carboxamide

8. Ruf 331

9. Xilep

10. Ruf-331

11. 1-[(2,6-difluorophenyl)methyl]triazole-4-carboxamide

12. E-2080

13. E2080

14. E 2080

15. Wfw942pr79

16. 1h-1,2,3-triazole-4-carboxamide, 1-[(2,6-difluorophenyl)methyl]-

17. Ncgc00165883-02

18. 1h-1,2,3-triazole-4-carboxamide, 1-((2,6-difluorophenyl)methyl)-

19. Dsstox_cid_26506

20. Dsstox_rid_81675

21. Dsstox_gsid_46506

22. 1-[(2,6-difluorophenyl)methyl]-1h-1,2,3-triazole-4 Carboxamide

23. Smr000857122

24. C10h8f2n4o

25. Cas-106308-44-5

26. Unii-wfw942pr79

27. Rufinamide [usan:inn:ban]

28. Syn111

29. Syn-111

30. Cgp33101

31. Banzel (tn)

32. Mfcd00865314

33. Rufinamide (banzel)

34. Cgp 33,101

35. Rufinamide [mi]

36. Rufinamide [inn]

37. Rufinamide [jan]

38. Rufinamide [usan]

39. Rufinamide [vandf]

40. Rufinamide [mart.]

41. Rufinamide [usp-rs]

42. Rufinamide [who-dd]

43. Rufinamide (jan/usp/inn)

44. Mls001332513

45. Mls001332514

46. Rufinamide [ema Epar]

47. Schembl230448

48. Gtpl7470

49. Zinc7782

50. Chembl1201754

51. Dtxsid1046506

52. Rufinamide [orange Book]

53. Chebi:134966

54. Hms2232m19

55. Hms3262o14

56. Hms3371a06

57. Hms3651o05

58. Hms3884g07

59. Rufinamide [usp Monograph]

60. Bcp21828

61. Hy-a0042

62. Tox21 112267

63. Tox21_112267

64. Tox21_500796

65. Bdbm50515492

66. S1256

67. Akos005145897

68. Rufinamide, >=98% (hplc), Powder

69. Tox21_112267_1

70. Ac-1429

71. Ccg-222100

72. Cs-1455

73. Db06201

74. Lp00796

75. Sb18904

76. Sdccgsbi-0633757.p001

77. Ncgc00165883-01

78. Ncgc00165883-03

79. Ncgc00165883-04

80. Ncgc00165883-11

81. Ncgc00261481-01

82. As-13861

83. Ft-0656828

84. Ft-0674479

85. R0143

86. Sw219770-1

87. C71253

88. D05775

89. Ab00918347-05

90. Ab00918347_06

91. 308r445

92. A801414

93. Q408565

94. Sr-01000842156

95. J-001568

96. Sr-01000842156-4

97. 1-[(2,6-difluorophenyl)methyl]-4-triazolecarboxamide

98. F0001-2404

99. Z1541638521

100. 1-(2,6-difluorobenzyl)-1h-1,2,3-triazol-4-carboxamide

101. Rufinamide, United States Pharmacopeia (usp) Reference Standard

102. 1-[[2,6-bis(fluoranyl)phenyl]methyl]-1,2,3-triazole-4-carboxamide

2.4 Create Date
2005-08-08
3 Chemical and Physical Properties
Molecular Weight 238.19 g/mol
Molecular Formula C10H8F2N4O
XLogP30.7
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count5
Rotatable Bond Count3
Exact Mass238.06661722 g/mol
Monoisotopic Mass238.06661722 g/mol
Topological Polar Surface Area73.8 Ų
Heavy Atom Count17
Formal Charge0
Complexity282
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameBanzel
PubMed HealthRufinamide (By mouth)
Drug ClassesAnticonvulsant
Drug LabelBANZEL (rufinamide) is a triazole derivative structurally unrelated to currently marketed antiepileptic drugs (AEDs). Rufinamide has the chemical name 1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-triazole-4 carboxamide. It has an empirical formula of C10H...
Active IngredientRufinamide
Dosage FormTablet; Suspension
RouteOral
Strength200mg; 40mg/ml; 400mg
Market StatusPrescription
CompanyEisai

2 of 2  
Drug NameBanzel
PubMed HealthRufinamide (By mouth)
Drug ClassesAnticonvulsant
Drug LabelBANZEL (rufinamide) is a triazole derivative structurally unrelated to currently marketed antiepileptic drugs (AEDs). Rufinamide has the chemical name 1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-triazole-4 carboxamide. It has an empirical formula of C10H...
Active IngredientRufinamide
Dosage FormTablet; Suspension
RouteOral
Strength200mg; 40mg/ml; 400mg
Market StatusPrescription
CompanyEisai

4.2 Drug Indication

Adjunct therapy for treatment of seizures associated with Lennox-Gastaut syndrome.


FDA Label


Inovelon is indicated as adjunctive therapy in the treatment of seizures associated with Lennox Gastaut syndrome in patients 4 years of age and older.


5 Pharmacology and Biochemistry
5.1 Pharmacology

At high concentrations will inhibit action of mGluR5 subtype receptors thus preventing the production of glutamate.


5.2 MeSH Pharmacological Classification

Voltage-Gated Sodium Channel Blockers

A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS. (See all compounds classified as Voltage-Gated Sodium Channel Blockers.)


Anticonvulsants

Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)


5.3 ATC Code

N03AF03


N03AF03

S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355


N - Nervous system

N03 - Antiepileptics

N03A - Antiepileptics

N03AF - Carboxamide derivatives

N03AF03 - Rufinamide


5.4 Absorption, Distribution and Excretion

Absorption

The oral suspension and tablet are bioequivalent on a mg per mg basis. Rufinamide is well absorbed but the rate is slow and the extent of absorption decreases as dose is increases. Based on urinary excretion, the extent of absorption was at least 85% following oral administration of a single dose of 600 mg rufinamide tablet under fed conditions. Bioavailability= 70%-85% (decreases with increasing doses); Tmax, fed and fasted states= 4-6 hours; Cmax, 10 mg/kg/day= 4.01 L/mL; Cmax, 30mg/kg/day= 8.68 L/mL; AUC (0h-12h), 10mg/kg/day= 37.847 gh/mL; AUC (0h-12h), 30mg/kg/day= 89.359 gh/mL.


Route of Elimination

Renally (91%; 66% as CGP 47292, 2% as unchanged drug) and fecally (9%) eliminated.


Volume of Distribution

Rufinamide was evenly distributed between erythrocytes and plasma. The apparent volume of distribution is dependent upon dose and varies with body surface area. The apparent volume of distribution was about 50 L at 3200 mg/day. Volume of distribution is similar between adults and children and is non-linear.


5.5 Metabolism/Metabolites

Rufinamide is extensively metabolized but has no active metabolites. Metabolism by carboxyesterases into inactive metabolite CGP 47292, a carboxylic acid derivative, via hydrolysis is the primary biotransformation pathway. A few minor additional metabolites were detected in urine, which appeared to be acyl-glucuronides of CGP 47292. The cytochrome P450 enzyme system or glutathiones are not involved with the metabolism of rufinamide. Rufinamide is a weak inhibitor of CYP 2E1. Rufinamide is a weak inducer of CYP 3A4 enzymes.


5.6 Biological Half-Life

Elimination half-life, healthy subjects and patients with epilepsy = 6-10 hours.


5.7 Mechanism of Action

Rufinamide is a triazole derivative antiepileptic that prolongs the inactive state of voltage gated sodium channels thus stabilizing membranes, ultimately blocking the spread of partial seizure activity.


API SUPPLIERS

read-more
read-more

01

Omgene Life Sciences Pvt. Ltd

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothOmgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Omgene Company Banner

02

Lupin Manufacturing Solutions

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

Flag India
Digital Content Digital Content
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Company Banner

03

Apotex Pharmachem

Canada

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BIO Partnering at JPM
Not Confirmed
arrow

Apotex Pharmachem

Canada

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BIO Partnering at JPM
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

04

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BIO Partnering at JPM
Not Confirmed
arrow

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BIO Partnering at JPM
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WCarrow-down NDC arrow-down KDMF VMF Others AUDIT arrow-down
blank

05

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BIO Partnering at JPM
Not Confirmed
arrow

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BIO Partnering at JPM
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WCarrow-down NDC arrow-down KDMF VMF Others AUDIT arrow-down
blank

06

Alivus Life Sciences

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BIO Partnering at JPM
Not Confirmed
arrow

Alivus Life Sciences

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BIO Partnering at JPM
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WCInactive-api NDC arrow-down KDMF VMF Others AUDIT arrow-down
blank

07

Micro Labs Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BIO Partnering at JPM
Not Confirmed
arrow

Micro Labs Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BIO Partnering at JPM
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
blank

08

Dipharma

Italy

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BIO Partnering at JPM
Not Confirmed
arrow

Dipharma

Italy

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BIO Partnering at JPM
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT arrow-down
blank

09

Hetero Drugs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BIO Partnering at JPM
Not Confirmed
arrow

Hetero Drugs

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BIO Partnering at JPM
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT arrow-down
blank

10

Zhejiang Jiuzhou Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BIO Partnering at JPM
Not Confirmed
arrow

Zhejiang Jiuzhou Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BIO Partnering at JPM
Not Confirmed
USDMF Inactive-api CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

Flag India
Digital Content Digital Content

GDUFA

DMF Review : Complete

Rev. Date : 2013-04-23

Pay. Date : 2012-11-13

DMF Number : 26316

Submission : 2012-10-09

Status : Active

Type : II

Company Banner

02

BIO Partnering at JPM
Not Confirmed

02

BIO Partnering at JPM
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2013-04-24

Pay. Date : 2012-11-06

DMF Number : 26209

Submission : 2012-10-23

Status : Active

Type : II

blank

03

Apotex Inc

Canada

USDMF

arrow
BIO Partnering at JPM
Not Confirmed

03

Apotex Inc

Canada
arrow
BIO Partnering at JPM
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2015-07-21

Pay. Date : 2015-03-16

DMF Number : 29034

Submission : 2015-03-27

Status : Active

Type : II

blank

04

Dipharma Francis Srl

Italy

USDMF

arrow
BIO Partnering at JPM
Not Confirmed

04

BIO Partnering at JPM
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2013-02-07

Pay. Date : 2012-11-09

DMF Number : 25676

Submission : 2012-01-04

Status : Active

Type : II

blank

05

Hetero Drugs Ltd

India

USDMF

arrow
BIO Partnering at JPM
Not Confirmed

05

BIO Partnering at JPM
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2021-10-07

Pay. Date : 2021-07-13

DMF Number : 36077

Submission : 2021-08-18

Status : Active

Type : II

blank

06

Micro Labs Ltd

India

USDMF

arrow
BIO Partnering at JPM
Not Confirmed

06

BIO Partnering at JPM
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2023-05-03

Pay. Date : 2023-04-12

DMF Number : 38182

Submission : 2023-03-23

Status : Active

Type : II

blank

07

BIO Partnering at JPM
Not Confirmed

07

BIO Partnering at JPM
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2018-09-10

Pay. Date : 2018-07-16

DMF Number : 32713

Submission : 2018-04-30

Status : Active

Type : II

blank

08

BIO Partnering at JPM
Not Confirmed

08

BIO Partnering at JPM
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2019-01-03

Pay. Date : 2018-07-26

DMF Number : 26385

Submission : 2012-09-29

Status : Active

Type : II

blank

09

BIO Partnering at JPM
Not Confirmed

09

BIO Partnering at JPM
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 28284

Submission : 2014-05-09

Status : Inactive

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

read-more
read-moreread-more

01

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Rufinamide USP

Date of Issue : 2022-07-06

Valid Till : 2025-06-25

Written Confirmation Number : WC-0057n

Address of the Firm : Plot No. 3109, GIDC, Industrial Estate Ankleshwar, Distt- Bharuch - 393002, Guja...

blank

02

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Rufinamide USP

Date of Issue : 2025-09-24

Valid Till : 2028-08-08

Written Confirmation Number : WC-0383

Address of the Firm : Unit-ll, Sy No * Parts of 454,455,457,458 & 459 Chandampet-Village, Shankarampet...

blank

03

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Rufinamide IH

Date of Issue : 2025-07-07

Valid Till : 2028-07-14

Written Confirmation Number : WC-0021

Address of the Firm : Sy. Nos, 317,320,321,322,323,604 & 605, Pincode-502329, Rudraram (Village), Pata...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-moreread-more

01

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

RUFINAMIDE

NDC Package Code : 50923-0614

Start Marketing Date : 2004-01-01

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

02

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

RUFINAMIDE

NDC Package Code : 66039-881

Start Marketing Date : 2012-10-23

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

03

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

RUFINAMIDE

NDC Package Code : 66005-0037

Start Marketing Date : 2011-01-10

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

04

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

RUFINAMIDE

NDC Package Code : 46438-0661

Start Marketing Date : 2021-04-15

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

05

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

RUFINAMIDE

NDC Package Code : 46438-0662

Start Marketing Date : 2021-04-15

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

06

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

RUFINAMIDE

NDC Package Code : 65977-0068

Start Marketing Date : 2008-11-14

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

07

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

RUFINAMIDE

NDC Package Code : 69766-050

Start Marketing Date : 2018-04-30

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

08

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

RUFINAMIDE

NDC Package Code : 14501-0058

Start Marketing Date : 2010-03-30

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothOmgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.

Flag India
Digital Content Digital Content

Rufinamide

About the Company : Omgene Life Sciences Pvt. Ltd. is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically integ...

Omgene Life Sciences Pvt. Ltd. is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically integrated company, we focus on developing high-quality formulations based on in-house-produced actives. With GMP-certified facilities and partnerships with contract manufacturers, we excel in formulation development for injectables, lyophilized injectables, complex generics, and oral peptide delivery systems, ensuring affordable, top-quality medicines. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Omgene Company Banner

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

Flag India
Digital Content Digital Content

Rufinamide

About the Company : Lupin Manufacturing Solutions (LMS), a wholly owned Lupin subsidiary, offers high-quality APIs and end-to-end CDMO services from R&D to commercial scale. Backed by five decades of ...

Lupin Manufacturing Solutions (LMS), a wholly owned Lupin subsidiary, offers high-quality APIs and end-to-end CDMO services from R&D to commercial scale. Backed by five decades of pharma expertise, LMS combines cost efficiency with regulatory excellence. With world-class sites in Dabhasa and Vizag, and an R&D center in Pune, we deliver integrated, sustainable, and globally compliant solutions that accelerate drug development and reduce environmental impact. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Company Banner

03

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Rufinamide

About the Company : Aspire group was established in the year 2000 with a motto of quality drug for better health of all. In its journey till date, aspire has developed enormous reputation, consistent ...

Aspire group was established in the year 2000 with a motto of quality drug for better health of all. In its journey till date, aspire has developed enormous reputation, consistent growth, unique technologies and world class quality healthcare products. Aspire is pioneer in manufacturing and sourcing unique healthcare products. True to the statement, “Where the future started yesterday” with a foresight on the current trends in the healthcare market, Aspire has grown from strength combining its research strength, Human resources and well established quality systems. Aspire has crossed numerous milestones in a comparatively short period since its inception.
blank

04

Dipharma

Italy
BIO Partnering at JPM
Not Confirmed
arrow

Dipharma

Italy
arrow
BIO Partnering at JPM
Not Confirmed

Rufinamide

About the Company : Dipharma is a leading European manufacturer of Active Pharmaceutical Ingredients that has been developing innovative and proprietary processes since 1949. We support our custome...

Dipharma is a leading European manufacturer of Active Pharmaceutical Ingredients that has been developing innovative and proprietary processes since 1949. We support our customers worldwide with a strong and well resourced R&D team, three cGMP facilities in Europe, and offer world-renowned expertise in handling hazardous chemical processes. Our customers can benefit from our broad portfolio of generic Active Pharmaceutical Ingredients and a wide range of advanced technologies available for custom synthesis. They can rely on the highest quality standards, but it does not stop there, they can count on our experience in innovation.
blank

05

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Rufinamide

About the Company : Glenmark was founded with a vision to emerge as a leading integrated research-based, global pharmaceutical company. Our branded generics business has a significant presence in mark...

Glenmark was founded with a vision to emerge as a leading integrated research-based, global pharmaceutical company. Our branded generics business has a significant presence in markets across emerging economies including India. The generics business services the requirements of developed markets like US and Western Europe. Our API business sells products in over 65 countries including the US, various countries in the EU, South America and India. With 15 manufacturing facilities and 3 R&D centers dedicated to the goal of enriching lives across the globe.
blank

06

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Rufinamide

About the Company : Indoco Remedies is engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs) in India. Indoco has a strong int...

Indoco Remedies is engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs) in India. Indoco has a strong international presence in the Regulated and Emerging markets. The Company is striving to place itself on a strong promising path by expanding its business strategically, strengthening its manufacturing facilities and enhancing capabilities across the organization. The Company is looking at various opportunities in untapped markets and association with business partners in the global markets to boost its revenues.
blank

07

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Rufinamide

About the Company : Micro Labs Limited is a diversified healthcare company with cutting-edge R&D, advanced manufacturing facilities, and a strong distribution network. It ranks among India's top pharm...

Micro Labs Limited is a diversified healthcare company with cutting-edge R&D, advanced manufacturing facilities, and a strong distribution network. It ranks among India's top pharmaceutical companies, with a leading presence in cardiology, diabetology, anti-infectives, ophthalmology, and pain management. The company is known for its high-quality medicines, including the popular fever management brand, Dolo. Micro Labs continues to grow through innovation, research, and global expansion, delivering healthcare solutions that meet international standards.
blank

08

Vasista

India
BIO Partnering at JPM
Not Confirmed
arrow

Vasista

India
arrow
BIO Partnering at JPM
Not Confirmed

Rufinamide

About the Company : Vasista Group, which includes Vasista Life Sciences Pvt Ltd. and Vasista Pharma Chem Pvt Ltd., we aim to be a leading player in the global healthcare industry. Since our inception,...

Vasista Group, which includes Vasista Life Sciences Pvt Ltd. and Vasista Pharma Chem Pvt Ltd., we aim to be a leading player in the global healthcare industry. Since our inception, we have specialized in providing a diverse range of chemistry-related services, from basic chemical entities to high-quality Active Pharmaceutical Ingredients (APIs). Our operations focus on three main areas: manufacturing and supplying APIs, intermediates, and fine chemicals, along with CRO and CMO activities. With state-of-the-art facilities, we are dedicated to meeting the dynamic needs of the global market while fostering innovation and trust.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1641925800,"product":"RUFINAMIDE (TAX INVOICE NO:1900216127 DA","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"BASLE","customer":"AIRPHARM PRATTELN BONDED WAREHOUSE","customerCountry":"SWITZERLAND","quantity":"40.00","actualQuantity":"40","unit":"KGS","unitRateFc":"2178","totalValueFC":"85631.7","currency":"USD","unitRateINR":159475,"date":"12-Jan-2022","totalValueINR":"6379000","totalValueInUsd":"85631.7","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"7433560","productDescription":"API","marketType":"REGULATED MARKET","country":"SWITZERLAND","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1642530600,"product":"RUFINAMIDE (TAX INVOICE NO:1900216180, D","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"NEWARK, NJ","customer":"MSN PHARMACEUTICALS INC","customerCountry":"UNITED STATES","quantity":"70.00","actualQuantity":"70","unit":"KGS","unitRateFc":"1400","totalValueFC":"95941.3","currency":"USD","unitRateINR":102100,"date":"19-Jan-2022","totalValueINR":"7147000","totalValueInUsd":"95941.3","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"7592971","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1651775400,"product":"RUFINAMIDE","address":"Plot 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth","city":"Solapur","supplier":"GLENMARK LIFE SCIENCES LTD","supplierCountry":"INDIA","foreign_port":"TEL AVIV YAFO","customer":"UNDISCLOSED","customerCountry":"ISRAEL","quantity":"55.00","actualQuantity":"55","unit":"KGS","unitRateFc":"1700","totalValueFC":"90042.5","currency":"USD","unitRateINR":126527.27272727272,"date":"06-May-2022","totalValueINR":"6959000","totalValueInUsd":"90042.5","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"1216079","productDescription":"API","marketType":"","country":"ISRAEL","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"Plot 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1655922600,"product":"RUFINAMIDE","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"BASLE","customer":"UNDISCLOSED","customerCountry":"SWITZERLAND","quantity":"40.00","actualQuantity":"40","unit":"KGS","unitRateFc":"2128.5","totalValueFC":"83842.5","currency":"USD","unitRateINR":163525,"date":"23-Jun-2022","totalValueINR":"6541000","totalValueInUsd":"83842.5","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"2331555","productDescription":"API","marketType":"REGULATED MARKET","country":"SWITZERLAND","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1710873000,"product":"RUFINAMIDE USP","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"BARCELONA","customer":"AIRPHARM BARCELONA BONDED WAREHOUSE","customerCountry":"SPAIN","quantity":"108.00","actualQuantity":"108","unit":"KGS","unitRateFc":"2079","totalValueFC":"221115","currency":"USD","unitRateINR":170004.26851851851,"date":"20-Mar-2024","totalValueINR":"18360461","totalValueInUsd":"221115","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"8480063","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1720117800,"product":"RUFINAMIDE-USP BATCH NO: RUF6O22002 (KG)( QTY- 0.200) TAX INV NO: 715201357\/29.06.2024","address":"NO 31, RACE COURSE ROAD,BANGALORE","city":"BENGALURU,KARNATAKA","supplier":"MICRO LABS LTD","supplierCountry":"INDIA","foreign_port":"HO CHI MINH C","customer":"ORIENT PHARMACEUTICAL CORP","customerCountry":"VIETNAM","quantity":"0.20","actualQuantity":"0.2","unit":"KGS","unitRateFc":"2000","totalValueFC":"265.8","currency":"USD","unitRateINR":111111.49999999999,"date":"05-Jul-2024","totalValueINR":"22222.3","totalValueInUsd":"265.8","indian_port":"Bangalore Air","hs_no":"29339990","bill_no":"2215915","productDescription":"API","marketType":"","country":"VIETNAM","selfForZScoreResived":"Pharma Grade","supplierPort":"Bangalore Air","supplierAddress":"NO 31, RACE COURSE ROAD,BANGALORE, BENGALURU,KARNATAKA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1722191400,"product":"RUFINAMIDE USP","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"BARCELONA","customer":"AIR PHARM BARCELONA BONDED WAREHOU","customerCountry":"SPAIN","quantity":"105.00","actualQuantity":"105","unit":"KGS","unitRateFc":"1980","totalValueFC":"205417.7","currency":"USD","unitRateINR":163534.1339047619,"date":"29-Jul-2024","totalValueINR":"17171084.06","totalValueInUsd":"205417.7","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"2797026","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1732818600,"product":"RUFINAMIDE USP","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"ANKARA","customer":"GEN ILAC VE SAGLIK URUNLERI","customerCountry":"TURKEY","quantity":"15.00","actualQuantity":"15","unit":"KGS","unitRateFc":"1600","totalValueFC":"23646.7","currency":"USD","unitRateINR":133033.60000000001,"date":"29-Nov-2024","totalValueINR":"1995504","totalValueInUsd":"23646.7","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"6026262","productDescription":"API","marketType":"","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1741804200,"product":"RUFINAMIDE USP","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"BARCELONA","customer":"AIRPHARM BARCELONA BONDED WAREHOUSE","customerCountry":"SPAIN","quantity":"115.00","actualQuantity":"115","unit":"KGS","unitRateFc":"1287","totalValueFC":"146573.8","currency":"USD","unitRateINR":110398.82173913044,"date":"13-Mar-2025","totalValueINR":"12695864.5","totalValueInUsd":"146573.8","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"8993117","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q3","strtotime":1756924200,"product":"RUFINAMIDE USP","address":"7-2-A2, HETERO CORPORATE,","city":"HYDERABAD-A.P.","supplier":"HETERO DRUGS LTD","supplierCountry":"INDIA","foreign_port":"TAIPEI","customer":"TWI PHARMACEUTICALS INC","customerCountry":"TAIWAN","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"2500","totalValueFC":"1163.7","currency":"USD","unitRateINR":205436,"date":"04-Sep-2025","totalValueINR":"102718","totalValueInUsd":"1163.7","indian_port":"Vizag-HIPL SEZ","hs_no":"29339990","bill_no":"5028026","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Vizag-HIPL SEZ","supplierAddress":"7-2-A2, HETERO CORPORATE,, HYDERABAD-A.P.","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1646677800,"product":"RUFINAMIDE-RUFINAMIDE USP (MICRONIZED)","address":"564\/A\/22, ROAD NO. 92,JUBILEE HILL S,","city":"HYDERABAD,TELANGANA","supplier":"DIPHARMA FRANCIS SRL","supplierCountry":"MALTA","foreign_port":"NA","customer":"MYLAN LABORATORIES LTD","customerCountry":"INDIA","quantity":"221.25","actualQuantity":"221.25","unit":"KGS","unitRateFc":"1840","totalValueFC":"409399.3","currency":"USD","unitRateINR":"141036","date":"08-Mar-2022","totalValueINR":"31204215","totalValueInUsd":"409399.3","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"7778160","productDescription":"API","marketType":"REGULATED MARKET","country":"MALTA","selfForZScoreResived":"Micronized","supplierPort":"NA","supplierAddress":"","customerAddress":"564\/A\/22, ROAD NO. 92,JUBILEE HILL S,"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1652293800,"product":"RUFINAMIDE USP (MICRONIZED)","address":"564\/A\/22, ROAD NO. 92,JUBILEE HILL S,","city":"HYDERABAD,TELANGANA","supplier":"DIPHARMA FRANCIS SRL","supplierCountry":"MALTA","foreign_port":"NA","customer":"MYLAN LABORATORIES LTD","customerCountry":"INDIA","quantity":"431.54","actualQuantity":"431.54","unit":"KGS","unitRateFc":"1840","totalValueFC":"791611.8","currency":"USD","unitRateINR":"141772","date":"12-May-2022","totalValueINR":"61180288.88","totalValueInUsd":"791611.8","indian_port":"BOMBAY AIR","hs_no":"29335990","bill_no":"8652609","productDescription":"API","marketType":"REGULATED MARKET","country":"MALTA","selfForZScoreResived":"Micronized","supplierPort":"NA","supplierAddress":"","customerAddress":"564\/A\/22, ROAD NO. 92,JUBILEE HILL S,"},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1657909800,"product":"RUFINAMIDE (QTY : 1 X 200 MG, PRICE USD: 757)(FOC)","address":"P.NO. D6 & D8, SY.NO. 234\/2,234\/3, ,235\/2 & 542\/2, IKP KNOWLEDGE PARK,","city":"TURKAPALLY-V SHAMIRPET HYDERABAD,TE","supplier":"UNDISCLOSED","supplierCountry":"INDIA","foreign_port":"NA","customer":"UNITED STATES PHARMACOPEIAINDIA PRIVATE LTD","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.0002","unit":"KGS","unitRateFc":"3785000","totalValueFC":"778","currency":"USD","unitRateINR":"309329900","date":"16-Jul-2022","totalValueINR":"61865.98","totalValueInUsd":"778","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"9575493","productDescription":"Re-Import","marketType":"REGULATED MARKET","country":"INDIA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"P.NO. D6 & D8, SY.NO. 234\/2,234\/3, ,235\/2 & 542\/2, IKP KNOWLEDGE PARK,"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1682447400,"product":"RUFINAMIDE RELATED COMPOUND A(QTY:2 X 25 MG,VALUE:USD 903\/EACH)(FOC)","address":"P.NO. D6 & D8, SY.NO. 234\/2,234\/3, ,235\/2 & 542\/2, IKP KNOWLEDGE PARK,","city":"TURKAPALLY-V SHAMIRPET HYDERABAD,TE","supplier":"UNDISCLOSED","supplierCountry":"INDIA","foreign_port":"NA","customer":"UNITED STATES PHARMACOPEIAINDIA PRIVATE LTD","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.00005","unit":"KGS","unitRateFc":"36120000","totalValueFC":"1932.1","currency":"USD","unitRateINR":"3166861600","date":"26-Apr-2023","totalValueINR":"158343.08","totalValueInUsd":"1932.1","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"5681755","productDescription":"Re-Import","marketType":"REGULATED MARKET","country":"INDIA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"P.NO. D6 & D8, SY.NO. 234\/2,234\/3, ,235\/2 & 542\/2, IKP KNOWLEDGE PARK,"},{"dataSource":"API Import","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1748543400,"product":"RUFINAMIDE USP","address":"HETERO CORPORATE, NO. 7-2-A2,,INDU","city":"HYDERABAD,TELANGANA","supplier":"HETERO DRUGS LTD UNIT IX","supplierCountry":"INDIA","foreign_port":"HIPL SEZ","customer":"HETERO LABS LTD","customerCountry":"INDIA","quantity":"185.00","actualQuantity":"185","unit":"KGS","unitRateFc":"1157.4","totalValueFC":"217134.5","currency":"USD","unitRateINR":"100000","date":"30-May-2025","totalValueINR":"18500000","totalValueInUsd":"217134.5","indian_port":"Vizag-HIPL SEZ","hs_no":"29339990","bill_no":"2363580","productDescription":"Re-Import","marketType":"REGULATED MARKET","country":"INDIA","selfForZScoreResived":"Pharma Grade","supplierPort":"HIPL SEZ","supplierAddress":"PLOT NO 1 HETERO INFRASTRUCTURE SEZ N.NARASAPURAM (V), NAKKAPALLY SDNF India","customerAddress":"HETERO CORPORATE, NO. 7-2-A2,,INDU"},{"dataSource":"API Import","activeIngredients":"","year":"2025","qtr":"Q3","strtotime":1756665000,"product":"RUFINAMIDE USP","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO DRUGS LTD UNIT IX","supplierCountry":"INDIA","foreign_port":"HIPL SEZ","customer":"HETERO LABS LTD","customerCountry":"INDIA","quantity":"206.86","actualQuantity":"206.86","unit":"KGS","unitRateFc":"1137.7","totalValueFC":"234351.7","currency":"USD","unitRateINR":"100000","date":"01-Sep-2025","totalValueINR":"20686000","totalValueInUsd":"234351.7","indian_port":"Vizag-HIPL SEZ","hs_no":"29339990","bill_no":"4232856","productDescription":"Re-Import","marketType":"REGULATED MARKET","country":"INDIA","selfForZScoreResived":"Pharma Grade","supplierPort":"HIPL SEZ","supplierAddress":"PLOT NO 1 HETERO INFRASTRUCTURE SEZ N.NARASAPURAM (V), NAKKAPALLY SDNF India","customerAddress":"HETERO CORPORATE, NO. 7-2-A2,"},{"dataSource":"API Import","activeIngredients":"","year":"2025","qtr":"Q3","strtotime":1758133800,"product":"RUFINAMIDE HPMC 2:3 PREMIX IH","address":"HETERO CORPORATE, NO. 7-2-A2,,INDU","city":"HYDERABAD,TELANGANA","supplier":"HETERO DRUGS LTD UNIT IX","supplierCountry":"INDIA","foreign_port":"HIPL SEZ","customer":"HETERO LABS LTD","customerCountry":"INDIA","quantity":"584.56","actualQuantity":"584.56","unit":"KGS","unitRateFc":"730.3","totalValueFC":"430461.2","currency":"USD","unitRateINR":"65000","date":"18-Sep-2025","totalValueINR":"37996400","totalValueInUsd":"430461.2","indian_port":"Vizag-HIPL SEZ","hs_no":"29339990","bill_no":"4573677","productDescription":"Re-Import","marketType":"REGULATED MARKET","country":"INDIA","selfForZScoreResived":"Pharma Grade","supplierPort":"HIPL SEZ","supplierAddress":"PLOT NO 1 HETERO INFRASTRUCTURE SEZ N.NARASAPURAM (V), NAKKAPALLY SDNF India","customerAddress":"HETERO CORPORATE, NO. 7-2-A2,,INDU"}]
12-Jan-2022
18-Sep-2025
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

read-more
read-more

Details:

Quizartinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.


Lead Product(s): Quizartinib,Rufinamide

Therapeutic Area: Undisclosed Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 18, 2024

blank

01

Biotech Showcase
Not Confirmed
Biotech Showcase
Not Confirmed

Details : Quizartinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

December 18, 2024

blank

Details:

Inovelon (rufinamide) is triazole derivative,believed to exert its antiepileptic effects by regulating activity of voltage-gated sodium channels in brain involved in overexcitement of neurons that potentially causes seizures, so as to prolong their inactive state.


Lead Product(s): Rufinamide,Inapplicable

Therapeutic Area: Rare Diseases and Disorders Brand Name: Inovelon

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 03, 2022

blank

02

Eisai

Japan
arrow
Biotech Showcase
Not Confirmed

Eisai

Japan
arrow
Biotech Showcase
Not Confirmed

Details : Inovelon (rufinamide) is triazole derivative,believed to exert its antiepileptic effects by regulating activity of voltage-gated sodium channels in brain involved in overexcitement of neurons that potentially causes seizures, so as to prolong their inact...

Product Name : Inovelon

Product Type : Miscellaneous

Upfront Cash : Inapplicable

November 03, 2022

blank

Details:

Rufinamide is used with other medication(s) to control seizures in people who have Lennox-Gastaut syndrome (a severe form of epilepsy that begins during childhood and causes several types of seizures, behavioral disturbances, and developmental delays).


Lead Product(s): Rufinamide,Inapplicable

Therapeutic Area: Rare Diseases and Disorders Brand Name: Rufinamide-Generic

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 18, 2022

blank

03

Lupin Ltd

India
arrow

Details : Rufinamide is used with other medication(s) to control seizures in people who have Lennox-Gastaut syndrome (a severe form of epilepsy that begins during childhood and causes several types of seizures, behavioral disturbances, and developmental delays).

Product Name : Rufinamide-Generic

Product Type : Miscellaneous

Upfront Cash : Inapplicable

August 18, 2022

blank

Details:

Rufinamide Oral Suspension, 40 mg/mL is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in pediatric patients 1 year of age and older, and in adults.


Lead Product(s): Rufinamide,Inapplicable

Therapeutic Area: Neurology Brand Name: Rufinamide-Generic

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 22, 2020

blank

04

Lupin Ltd

India
arrow

Details : Rufinamide Oral Suspension, 40 mg/mL is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in pediatric patients 1 year of age and older, and in adults.

Product Name : Rufinamide-Generic

Product Type : Miscellaneous

Upfront Cash : Inapplicable

December 22, 2020

blank

Details:

Rufinamide is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Lennox Gastaut Syndrome.


Lead Product(s): Rufinamide,Inapplicable

Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed

Study Phase: UndisclosedProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 19, 2018

blank

05

Eisai Inc

U.S.A
arrow
Biotech Showcase
Not Confirmed

Eisai Inc

U.S.A
arrow
Biotech Showcase
Not Confirmed

Details : Rufinamide is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Lennox Gastaut Syndrome.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

December 19, 2018

blank

Details:

Rufinamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lennox Gastaut Syndrome.


Lead Product(s): Rufinamide,Inapplicable

Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 29, 2011

blank

06

Eisai Inc

U.S.A
arrow
Biotech Showcase
Not Confirmed

Eisai Inc

U.S.A
arrow
Biotech Showcase
Not Confirmed

Details : Rufinamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lennox Gastaut Syndrome.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

July 29, 2011

blank

Details:

Rufinamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lennox Gastaut Syndrome.


Lead Product(s): Rufinamide,Inapplicable

Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 28, 2010

blank

07

Eisai

Japan
arrow
Biotech Showcase
Not Confirmed

Eisai

Japan
arrow
Biotech Showcase
Not Confirmed

Details : Rufinamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lennox Gastaut Syndrome.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

June 28, 2010

blank

Details:

Rufinamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lennox Gastaut Syndrome.


Lead Product(s): Rufinamide,Inapplicable

Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 22, 2010

blank

08

Eisai Inc

U.S.A
arrow
Biotech Showcase
Not Confirmed

Eisai Inc

U.S.A
arrow
Biotech Showcase
Not Confirmed

Details : Rufinamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lennox Gastaut Syndrome.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

June 22, 2010

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

INTERMEDIATE SUPPLIERS

read-more
read-more

01

BIO Partnering at JPM
Not Confirmed
arrow
BIO Partnering at JPM
Not Confirmed
arrow

CAS Number : 530-78-9

End Use API : Rufinamide

About The Company : Established in 2000, Shodhana Laboratories offers a wide range of APIs and intermediates and caters to the generic and custom requirements of some of the most p...

blank

02

BIO Partnering at JPM
Not Confirmed
arrow
BIO Partnering at JPM
Not Confirmed
arrow

CAS Number : 924-99-2

End Use API : Rufinamide

About The Company : Vasista Group, which includes Vasista Life Sciences Pvt Ltd. and Vasista Pharma Chem Pvt Ltd., we aim to be a leading player in the global healthcare industry. ...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

read-more
read-more

01

Eisai Gmbh

Japan
BIO Partnering at JPM
Not Confirmed
arrow

Eisai Gmbh

Japan
arrow
BIO Partnering at JPM
Not Confirmed

Rufinamid

Brand Name : Inovelon

Dosage Form : Film Coated Tablet

Dosage Strength : 200mg

Packaging :

Approval Date : 16/01/2007

Application Number : 20050406000047

Regulatory Info : Approved

Registration Country : Sweden

blank

02

Eisai Gmbh

Japan
BIO Partnering at JPM
Not Confirmed
arrow

Eisai Gmbh

Japan
arrow
BIO Partnering at JPM
Not Confirmed

Rufinamid

Brand Name : Inovelon

Dosage Form : Film Coated Tablet

Dosage Strength : 400mg

Packaging :

Approval Date : 16/01/2007

Application Number : 20050406000054

Regulatory Info : Approved

Registration Country : Sweden

blank

03

Eisai Gmbh

Japan
BIO Partnering at JPM
Not Confirmed
arrow

Eisai Gmbh

Japan
arrow
BIO Partnering at JPM
Not Confirmed

Rufinamide

Brand Name : Inovelon

Dosage Form : Oral Suspension

Dosage Strength : 40MG

Packaging :

Approval Date : 2012-03-20

Application Number : 06378017

Regulatory Info : Authorized

Registration Country : Spain

blank

04

Eisai Gmbh

Japan
BIO Partnering at JPM
Not Confirmed
arrow

Eisai Gmbh

Japan
arrow
BIO Partnering at JPM
Not Confirmed

Rufinamide

Brand Name : Inovelon

Dosage Form : Film Coated Tablet

Dosage Strength : 100MG

Packaging :

Approval Date : 2007-07-31

Application Number : 06378001

Regulatory Info : Authorized

Registration Country : Spain

blank

05

Eisai Gmbh

Japan
BIO Partnering at JPM
Not Confirmed
arrow

Eisai Gmbh

Japan
arrow
BIO Partnering at JPM
Not Confirmed

Rufinamide

Brand Name : Inovelon

Dosage Form : Film Coated Tablet

Dosage Strength : 400MG

Packaging :

Approval Date : 2007-07-31

Application Number : 06378015

Regulatory Info : Authorized

Registration Country : Spain

blank

06

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Rufinamide

Brand Name : Inovelon

Dosage Form : Rufinamide 200Mg 60 Units Oral Use

Dosage Strength : 60 cpr riv 200 mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Italy

blank

07

Eisai Ltd

U.S.A
BIO Partnering at JPM
Not Confirmed
arrow

Eisai Ltd

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

Rufinamide

Brand Name : Inovelon

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 100 mg

Packaging : Blister

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

08

Eisai Ltd

U.S.A
BIO Partnering at JPM
Not Confirmed
arrow

Eisai Ltd

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

Rufinamide

Brand Name : Inovelon

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 200 mg

Packaging : Blister

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

09

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Rufinamidum

Brand Name : Inovelon

Dosage Form : Film Coated Tablet

Dosage Strength : 200mg

Packaging :

Approval Date : 06/01/2009

Application Number : 58097

Regulatory Info : Allowed

Registration Country : Switzerland

blank

10

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Rufinamidum

Brand Name : Inovelon

Dosage Form : Film Coated Tablet

Dosage Strength : 400mg

Packaging :

Approval Date : 06/01/2009

Application Number : 58097

Regulatory Info : Allowed

Registration Country : Switzerland

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

DRUG PRODUCT COMPOSITIONS

Do you need Business Intel? Ask us

DOSAGE - SUSPENSION;ORAL - 40MG/ML

USFDA APPLICATION NUMBER - 201367

read-more

DOSAGE - TABLET;ORAL - 100MG **Federal Regist...DOSAGE - TABLET;ORAL - 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

USFDA APPLICATION NUMBER - 21911

read-more

DOSAGE - TABLET;ORAL - 200MG

USFDA APPLICATION NUMBER - 21911

read-more

DOSAGE - TABLET;ORAL - 400MG

USFDA APPLICATION NUMBER - 21911

read-more

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Coating Systems & Additives

read-more
read-more

Fillers, Diluents & Binders

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Direct Compression

read-more
read-more

Controlled & Modified Release

read-more
read-more

Granulation

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Topical

read-more
read-more

Lubricants & Glidants

read-more
read-more

Taste Masking

read-more
read-more

Rheology Modifiers

read-more
read-more

Solubilizers

read-more
read-more

Co-Processed Excipients

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Emulsifying Agents

read-more
read-more

Parenteral

read-more
read-more

Empty Capsules

read-more
read-more

API Stability Enhancers

read-more
read-more

Coloring Agents

read-more
read-more

Vegetarian Capsules

read-more
read-more

Surfactant & Foaming Agents

read-more
read-more

Soft Gelatin

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ANALYTICAL

Upload your methods for free, ask us

ABOUT THIS PAGE

Looking for 106308-44-5 / Rufinamide API manufacturers, exporters & distributors?

Rufinamide manufacturers, exporters & distributors 1

92

PharmaCompass offers a list of Rufinamide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Rufinamide manufacturer or Rufinamide supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Rufinamide manufacturer or Rufinamide supplier.

PharmaCompass also assists you with knowing the Rufinamide API Price utilized in the formulation of products. Rufinamide API Price is not always fixed or binding as the Rufinamide Price is obtained through a variety of data sources. The Rufinamide Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Rufinamide

Synonyms

106308-44-5, Banzel, Inovelon, 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide, Cgp 33101, Cgp-33101

Cas Number

106308-44-5

Unique Ingredient Identifier (UNII)

WFW942PR79

About Rufinamide

Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures.

Banzel Manufacturers

A Banzel manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Banzel, including repackagers and relabelers. The FDA regulates Banzel manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Banzel API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Banzel manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Banzel Suppliers

A Banzel supplier is an individual or a company that provides Banzel active pharmaceutical ingredient (API) or Banzel finished formulations upon request. The Banzel suppliers may include Banzel API manufacturers, exporters, distributors and traders.

click here to find a list of Banzel suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Banzel USDMF

A Banzel DMF (Drug Master File) is a document detailing the whole manufacturing process of Banzel active pharmaceutical ingredient (API) in detail. Different forms of Banzel DMFs exist exist since differing nations have different regulations, such as Banzel USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Banzel DMF submitted to regulatory agencies in the US is known as a USDMF. Banzel USDMF includes data on Banzel's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Banzel USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Banzel suppliers with USDMF on PharmaCompass.

Banzel WC

A Banzel written confirmation (Banzel WC) is an official document issued by a regulatory agency to a Banzel manufacturer, verifying that the manufacturing facility of a Banzel active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Banzel APIs or Banzel finished pharmaceutical products to another nation, regulatory agencies frequently require a Banzel WC (written confirmation) as part of the regulatory process.

click here to find a list of Banzel suppliers with Written Confirmation (WC) on PharmaCompass.

Banzel NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Banzel as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Banzel API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Banzel as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Banzel and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Banzel NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Banzel suppliers with NDC on PharmaCompass.

Banzel GMP

Banzel Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Banzel GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Banzel GMP manufacturer or Banzel GMP API supplier for your needs.

Banzel CoA

A Banzel CoA (Certificate of Analysis) is a formal document that attests to Banzel's compliance with Banzel specifications and serves as a tool for batch-level quality control.

Banzel CoA mostly includes findings from lab analyses of a specific batch. For each Banzel CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Banzel may be tested according to a variety of international standards, such as European Pharmacopoeia (Banzel EP), Banzel JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Banzel USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty